NASDAQ:ALLK - Allakos Stock Price, Forecast & News

Allakos trades on the NASDAQ under the ticker symbol "ALLK."

Allakos Inc (NASDAQ:ALLK) issued its earnings results on Tuesday, November, 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.43) by $0.04. View Allakos' Earnings History.

Allakos is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Allakos.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allakos.

Media headlines about ALLK stock have trended somewhat negative on Monday, InfoTrie reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allakos earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Allakos.

Some companies that are related to Allakos include Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Elanco Animal Health (ELAN), Mylan (MYL), Teva Pharmaceutical Industries (TEVA), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Catalent (CTLT), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Amarin (AMRN) and Dr.Reddy's Laboratories (RDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include Advanced Micro Devices (AMD), Eiger Biopharmaceuticals (EIGR), Gilead Sciences (GILD), Heron Therapeutics (HRTX), AbbVie (ABBV), General Motors (GM), Pfizer (PFE), Exxon Mobil (XOM), Agios Pharmaceuticals (AGIO) and Align Technology (ALGN).

(ALLK) raised $96 million in an initial public offering (IPO) on Thursday, July 19th 2018. The company issued 6,000,000 shares at $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager.

Allakos' stock is owned by many different of retail and institutional investors. Top institutional investors include Alpine Global Management LLC (0.00%), Strs Ohio (0.00%) and Nisa Investment Advisors LLC (0.00%). Company insiders that own Allakos stock include Daniel Janney, John P Mckearn and Venture Fund (Ohi Rivervest II. View Institutional Ownership Trends for Allakos.

ALLK stock was acquired by a variety of institutional investors in the last quarter, including Alpine Global Management LLC, Strs Ohio and Nisa Investment Advisors LLC. Company insiders that have bought Allakos stock in the last two years include Daniel Janney and Venture Fund (Ohi Rivervest II. View Insider Buying and Selling for Allakos.

Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ALLK stock can currently be purchased for approximately $73.60.

Allakos has a market capitalization of $3.58 billion. The company earns $-43,540,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. Allakos employs 62 workers across the globe.View Additional Information About Allakos.

The official website for Allakos is http://www.allakos.com/.

Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-597-5002 or via email at [email protected]